Copeptin and insulin resistance: effect modification by age and 11 β-HSD2 activity in a population-based study.

TitreCopeptin and insulin resistance: effect modification by age and 11 β-HSD2 activity in a population-based study.
Publication TypeJournal Article
Year of Publication2018
AuthorsCanivell, S, Mohaupt, M, Ackermann, D, Pruijm, M, Guessous, I, Ehret, G, Escher, G, Pechère-Bertschi, A, Vogt, B, Devuyst, O, Burnier, M, Martin, P-Y, Ponte, B, Bochud, M
JournalJournal of endocrinological investigation
Volume41
Issue7
Pagination799-808
Date Published07/2018
DOI10.1007/s40618-017-0807-7
ISSN1720-8386
Mots-clés11-beta-Hydroxysteroid Dehydrogenase Type 2/metabolism, 11-β hydroxysteroid dehydrogenase type 2 enzyme, 80 and over, Adult, Age Factors, Aged, Aging, Aging/blood, Aging/metabolism, Copeptin, Cross-Sectional Studies, Diabetes Mellitus, Female, Glycopeptides/blood, Humans, Insulin Resistance, Insulin Resistance/physiology, Interaction, Male, Metabolic, Middle Aged, Syndrome/metabolism, Type 2/complications, Type 2/metabolism, Young Adult
Abstract

PURPOSE: Arginine vasopressin (AVP) may be involved in metabolic syndrome (MetS) by altering liver glycogenolysis, insulin and glucagon secretion, and pituitary ACTH release. Moreover, AVP stimulates the expression of 11β-hydroxysteroid-dehydrogenase-type 2 (11β-HSD2) in mineralocorticosteroid cells. We explored whether apparent 11β-HSD2 activity, estimated using urinary cortisol-to-cortisone ratio, modulates the association between plasma copeptin, as AVP surrogate, and insulin resistance/MetS in the general adult population.

METHODS: This was a multicentric, family-based, cross-sectional sample of 1089 subjects, aged 18-90 years, 47% men, 13.4% MetS, in Switzerland. Mixed multivariable linear and logistic regression models were built to investigate the association of insulin resistance (HOMA-IR)/fasting glucose and MetS/Type 2 Diabetes with copeptin, while considering potential confounders or effect modifiers into account. Stratified results by age and 11β-HSD2 activity were presented as appropriate.

RESULTS: Plasma copeptin was higher in men [median 5.2, IQR (3.7-7.8) pmol/L] than in women [median 3.0, IQR (2.2-4.3) pmol/L], P < 0.0001. HOMA-IR was positively associated with copeptin after full adjustment if 11β-HSD2 activity was high [β (95% CI) = 0.32 (0.17-0.46), P < 0.001] or if age was high [β (95% CI) = 0.34 (0.20-0.48), P < 0.001], but not if either 11β-HSD2 activity or age was low. There was a positive association of type 2 diabetes with copeptin [OR (95% CI) = 2.07 (1.10-3.89), P = 0.024), but not for MetS (OR (95% CI) = 1.12 (0.74-1.69), P = 0.605), after full adjustment.

CONCLUSIONS: Our data suggest that age and apparent 11β-HSD2 activity modulate the association of copeptin with insulin resistance at the population level but not MeTS or diabetes. Further research is needed to corroborate these results and to understand the mechanisms underlying these findings.

Alternate URL

http://www.ncbi.nlm.nih.gov/pubmed/29235050?dopt=Abstract

First publication date (online)

12/2017

WOS ID (UT)

000435589900007

Alternate JournalJ. Endocrinol. Invest.
Citation Key / SERVAL ID8468
Peer reviewRefereed
PubMed ID29235050
Grant ListFN 33CM30-124087 / / Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung / United States
Tremplin funding / / Hôpitaux Universitaires de Genève / United States
Albert Renold Fellowship / / European Foundation for the Study of Diabetes / United States

                         

IUMSP | www.iumsp.ch
Institut universitaire de médecine sociale et préventive
Route de la Corniche 10, 1010 Lausanne - Switzerland
+41 21 314 72 72 | dess.info@unisante.ch

Go to top